Area holds right prescription for booming industry

Imagine there’s a test that can tell you if you’re going to have a heart attack in the near future.

A group of Boulder researchers at MiRagen Therapeutics Inc. do research that could lead to just such a test. They have found that heightened levels of the molecule they have named MIR-208 in the blood can lead to heart damage and heart failure, said Bill Marshall, chief executive officer and a founder of the company.

The researchers came up with test information as they worked on creating a new heart disease treatment drug. They set up studies to monitor microRNA variations in…